Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 35

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 35
---
, or until November 20, 2024 (the “Compliance Date”),
to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the MVLS for the Class A Shares is at least
$50,000,000 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with
the MVLS Requirement. In the event the Company does not regain compliance with the above requirement prior to the expiration of the compliance
period, it will receive written notification that its securities are subject to delisting.

On May 24, 2024, the Company
received a deficiency letter (“MVPHS Deficiency Letter”) from the Staff of Nasdaq notifying the Company that, for the preceding
35 consecutive business days, the Company’s Class A Ordinary Shares did not meet the minimum $15,000,000 Market Value of Publicly
Held Shares (“MVPHS”) requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C) (the “MVPHS
Requirement,” and the Company’s non-compliance with this requirement, the “MVPHS Deficiency”). In accordance with
Nasdaq Rule 5810(c)(3)(D), the Company has until the Compliance Date to regain compliance with the MVPHS Requirement. If, at any time
before the Compliance Date, the MVPHS for the Class A Shares is at least $15,000,000 for a minimum of ten consecutive business days, the
Staff will provide the Company written confirmation of compliance with the MVPHS Requirement. In the event the Company does not regain
compliance with the above requirement prior to the expiration of the compliance period, it will receive written notification that its
securities are subject to delisting. Alternatively, the Company may apply to transfer the Company’s securities to The Nasdaq Capital
Market.

On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the “Panel”) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at an oral hearing on January 28, 2025 (